Skip Navigation

Rheumatology 2006 45(Supplement 4):iv14-iv17; doi:10.1093/rheumatology/kel312
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Kahan, A.
Right arrow Articles by Allanore, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kahan, A.
Right arrow Articles by Allanore, Y.
Related Collections
Right arrow Systemic Sclerosis
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Primary myocardial involvement in systemic sclerosis

A. Kahan and Y. Allanore

Paris 5 René Descartes University, Department of Rheumatology A, Cochin Hospital, AP-HP, Paris, France.

Correspondence to: Prof. André Kahan, Service de Rhumatologie A, Hôpital Cochin, 27 rue du Faubourg Saint-Jacques, 75014 Paris, France. E-mail: andre.kahan{at}cch.aphp.fr

Systemic sclerosis (SSc) is a connective tissue disease characterized by diffuse vascular lesions and fibrosis. Primary myocardial involvement is common in SSc and, when clinically evident, appears as a poor prognostic factor. An increasing body of evidence suggests that myocardial involvement is due, at least in part, to microcirculation impairment with abnormal vasoreactivity, with or without associated structural abnormalities of the small coronary arteries or arterioles.

Using conventional methods, myocardial perfusion impairment, systolic and diastolic left ventricular dysfunction and right ventricular dysfunction have been reported in SSc. Recently, tissue Doppler echocardiography and magnetic resonance imaging have confirmed these results. Vasodilators, such as calcium channel blockers and angiotensin converting enzyme inhibitors, improve both myocardial perfusion and function abnormalities.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 The Journal of RheumatologyHome page
Y. SCHOINDRE, C. MEUNE, A. T. DINH-XUAN, J. AVOUAC, A. KAHAN, and Y. ALLANORE
Lack of Specificity of the 6-Minute Walk Test as an Outcome Measure for Patients with Systemic Sclerosis
J Rheumatol, July 1, 2009; 36(7): 1481 - 1485.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
A. Kahan, G. Coghlan, and V. McLaughlin
Cardiac complications of systemic sclerosis
Rheumatology, June 1, 2009; 48(suppl_3): iii45 - iii48.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
Y. Allanore, C. Meune, and A. Kahan
Outcome measures for heart involvement in systemic sclerosis
Rheumatology, October 1, 2008; 47(suppl_5): v51 - v53.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
L. Belloli, N. Carlo-Stella, G. Ciocia, A. Chiti, M. Massarotti, and B. Marasini
Myocardial involvement in systemic sclerosis
Rheumatology, July 1, 2008; 47(7): 1070 - 1072.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.